Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

290 Views

Poster Session: Clinical Trials

225 - Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Co-Author(s)

Alita Miller, PhD

CSO
Entasis Therapeutics
Waltham, Massachusetts, United States
AS

Adam B. Shapiro, Ph.D

Research Fellow
Entasis Therapeutics
Waltham, Massachusetts, United States
Sarah McLeod, PhD (she/her/hers)

Director
Entasis Therapeutics
Waltham, Massachusetts, United States

Presenting Author(s)

Khurram Rana, PharmD

Director, Clinical Scientist
Entasis Therapeutics
Waltham, Massachusetts, United States

Co-Author(s)

DL

Drew Lewis, MD, MTM&H

Vice President, Clinical Development
Entasis Therapeutics
Waltham, Massachusetts, United States
David Altarac, MD, MPA

Chief Medical Officer
Entasis Therapeutics
Waltham, MA, United States